Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

LPCN Relative to the S&P 500

LPCN Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Lipocine Inc. (NASD:LPCN) seasonal charts above shows that a Buy Date of May 13 and a Sell Date of August 13 has resulted in a geometric average return of 10.21% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 51.9% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

To download LPCN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: LPCN